Literature DB >> 25304930

The paracrine hormone for the GUCY2C tumor suppressor, guanylin, is universally lost in colorectal cancer.

Chantell Wilson1, Jieru E Lin1, Peng Li1, Adam E Snook1, Jianping Gong1, Takahiro Sato2, Chengbao Liu2, Melanie A Girondo2, Hallgeir Rui2, Terry Hyslop1, Scott A Waldman3.   

Abstract

BACKGROUND: Although colorectal cancer is a disease characterized by sequential accumulation of mutations in epithelial cells, mechanisms leading to genomic vulnerability contributing to tumor initiation remain undefined. GUCY2C has emerged as an intestine-specific tumor suppressor controlling epithelial homeostasis through circuits canonically disrupted in cancer. Surprisingly, the GUCY2C tumor suppressor is universally overexpressed by human colorectal cancer cells. This apparent paradox likely reflects silencing of GUCY2C through loss of its paracrine hormone guanylin. Here, we quantified expression of guanylin mRNA and protein in tumors and normal epithelia from patients with colorectal cancer.
METHODS: Guanylin mRNA was quantified in tumors and normal adjacent epithelia from 281 patients by the reverse transcriptase-polymerase chain reaction. Separately, the guanylin protein was quantified by immunohistochemistry in 54 colorectal tumors and 30 specimens of normal intestinal epithelium.
RESULTS: Guanylin mRNA in colorectum varied more than a 100-fold across the population. Guanylin mRNA was reduced 100- to 1,000-fold in >85% of tumors compared with matched normal adjacent mucosa (P < 0.001). Loss of guanylin mRNA was greatest in tumors from patients <50 years old (P < 0.005) and with the highest expression in normal adjacent mucosa (Spearman correlation coefficient = 0.61; P < 0.001). In a separate validation cohort, guanylin protein was detected in all 30 normal colorectal mucosa specimens, but in none of 54 colorectal tumors.
CONCLUSIONS: Colorectal cancer may initiate as a disease of paracrine hormone insufficiency through loss of guanylin expression, silencing the GUCY2C tumor suppressor and disrupting homeostatic mechanisms regulating colorectal epithelia cells. IMPACT: Intestinal tumorigenesis may be prevented by oral GUCY2C hormone replacement therapy. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25304930      PMCID: PMC4221461          DOI: 10.1158/1055-9965.EPI-14-0440

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  37 in total

1.  Maximum likelihood inference for left-censored HIV RNA data.

Authors:  H S Lynn
Journal:  Stat Med       Date:  2001-01-15       Impact factor: 2.373

Review 2.  Guanylyl cyclases and signaling by cyclic GMP.

Authors:  K A Lucas; G M Pitari; S Kazerounian; I Ruiz-Stewart; J Park; S Schulz; K P Chepenik; S A Waldman
Journal:  Pharmacol Rev       Date:  2000-09       Impact factor: 25.468

3.  Guanylyl cyclase C agonists regulate progression through the cell cycle of human colon carcinoma cells.

Authors:  G M Pitari; M D Di Guglielmo; J Park; S Schulz; S A Waldman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-03       Impact factor: 11.205

4.  Transcriptional gene expression profiles of colorectal adenoma, adenocarcinoma, and normal tissue examined by oligonucleotide arrays.

Authors:  D A Notterman; U Alon; A J Sierk; A J Levine
Journal:  Cancer Res       Date:  2001-04-01       Impact factor: 12.701

5.  Guanylyl cyclase C messenger RNA is a biomarker for recurrent stage II colorectal cancer.

Authors:  B Cagir; A Gelmann; J Park; T Fava; A Tankelevitch; E W Bittner; E J Weaver; J P Palazzo; D Weinberg; R D Fry; S A Waldman
Journal:  Ann Intern Med       Date:  1999-12-07       Impact factor: 25.391

6.  Uroguanylin treatment suppresses polyp formation in the Apc(Min/+) mouse and induces apoptosis in human colon adenocarcinoma cells via cyclic GMP.

Authors:  K Shailubhai; H H Yu; K Karunanandaa; J Y Wang; S L Eber; Y Wang; N S Joo; H D Kim; B W Miedema; S Z Abbas; S S Boddupalli; M G Currie; L R Forte
Journal:  Cancer Res       Date:  2000-09-15       Impact factor: 12.701

7.  Bacterial enterotoxins are associated with resistance to colon cancer.

Authors:  G M Pitari; L V Zingman; D M Hodgson; A E Alekseev; S Kazerounian; M Bienengraeber; G Hajnóczky; A Terzic; S A Waldman
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-19       Impact factor: 11.205

8.  Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic, and tissue array profiling.

Authors:  Satoshi Nishizuka; Sing-Tsung Chen; Fuad G Gwadry; Jes Alexander; Sylvia M Major; Uwe Scherf; William C Reinhold; Mark Waltham; Lu Charboneau; Lynn Young; Kimberly J Bussey; Sohyoung Kim; Samir Lababidi; Jae K Lee; Stefania Pittaluga; Dominic A Scudiero; Edward A Sausville; Peter J Munson; Emmanuel F Petricoin; Lance A Liotta; Stephen M Hewitt; Mark Raffeld; John N Weinstein
Journal:  Cancer Res       Date:  2003-09-01       Impact factor: 12.701

9.  Intestinal GUCY2C prevents TGF-β secretion coordinating desmoplasia and hyperproliferation in colorectal cancer.

Authors:  Ahmara V Gibbons; Jieru E Lin; Gilbert W Kim; Glen P Marszalowicz; Peng Li; Brian A Stoecker; Erik S Blomain; Satish Rattan; Adam E Snook; Stephanie Schulz; Scott A Waldman
Journal:  Cancer Res       Date:  2013-10-01       Impact factor: 12.701

10.  Gene expression in colorectal cancer.

Authors:  Karin Birkenkamp-Demtroder; Lise Lotte Christensen; Sanne Harder Olesen; Casper M Frederiksen; Päivi Laiho; Lauri A Aaltonen; Søren Laurberg; Flemming B Sørensen; Rikke Hagemann; Torben F ØRntoft
Journal:  Cancer Res       Date:  2002-08-01       Impact factor: 12.701

View more
  29 in total

Review 1.  From bedside to bench--meeting report of the 7th International Conference on cGMP "cGMP: generators, effectors and therapeutic implications" in Trier, Germany, from June 19th to 21st 2015.

Authors:  Andreas Friebe; Peter Sandner; Roland Seifert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-10-20       Impact factor: 3.000

Review 2.  GUCY2C ligand replacement to prevent colorectal cancer.

Authors:  Erik S Blomain; Amanda M Pattison; Scott A Waldman
Journal:  Cancer Biol Ther       Date:  2016-04-22       Impact factor: 4.742

3.  GUCY2C Signaling Opposes the Acute Radiation-Induced GI Syndrome.

Authors:  Peng Li; Evan Wuthrick; Jeff A Rappaport; Crystal Kraft; Jieru E Lin; Glen Marszalowicz; Adam E Snook; Tingting Zhan; Terry M Hyslop; Scott A Waldman
Journal:  Cancer Res       Date:  2017-09-15       Impact factor: 12.701

4.  Cyclic-GMP-Elevating Agents Suppress Polyposis in ApcMin mice by Targeting the Preneoplastic Epithelium.

Authors:  Sarah K Sharman; Bianca N Islam; Yali Hou; Nagendra Singh; Franklin G Berger; Subbaramiah Sridhar; Wonsuk Yoo; Darren D Browning
Journal:  Cancer Prev Res (Phila)       Date:  2018-01-04

5.  Sildenafil Suppresses Inflammation-Driven Colorectal Cancer in Mice.

Authors:  Bianca N Islam; Sarah K Sharman; Yali Hou; Allison E Bridges; Nagendra Singh; Sangmi Kim; Ravindra Kolhe; Jimena Trillo-Tinoco; Paulo C Rodriguez; Franklin G Berger; Subbaramiah Sridhar; Darren D Browning
Journal:  Cancer Prev Res (Phila)       Date:  2017-05-03

Review 6.  Guanylate cyclase C as a target for prevention, detection, and therapy in colorectal cancer.

Authors:  Allison A Aka; Jeff A Rappaport; Amanda M Pattison; Takami Sato; Adam E Snook; Scott A Waldman
Journal:  Expert Rev Clin Pharmacol       Date:  2017-04-10       Impact factor: 5.045

7.  Obesity-Induced Colorectal Cancer Is Driven by Caloric Silencing of the Guanylin-GUCY2C Paracrine Signaling Axis.

Authors:  Jieru E Lin; Francheska Colon-Gonzalez; Erik Blomain; Gilbert W Kim; Amanda Aing; Brian Stoecker; Justin Rock; Adam E Snook; Tingting Zhan; Terry M Hyslop; Michal Tomczak; Richard S Blumberg; Scott A Waldman
Journal:  Cancer Res       Date:  2016-01-15       Impact factor: 12.701

8.  Does obesity promote the development of colorectal cancer?

Authors:  Erik S Blomain; Scott A Waldman
Journal:  Expert Rev Anticancer Ther       Date:  2016-03-24       Impact factor: 4.512

Review 9.  Guanylyl Cyclase C Hormone Axis at the Intersection of Obesity and Colorectal Cancer.

Authors:  Erik S Blomain; Dante J Merlino; Amanda M Pattison; Adam E Snook; Scott A Waldman
Journal:  Mol Pharmacol       Date:  2016-06-01       Impact factor: 4.436

10.  GUCY2C as a biomarker to target precision therapies for patients with colorectal cancer.

Authors:  Amanda N Lisby; John C Flickinger; Babar Bashir; Megan Weindorfer; Sanjna Shelukar; Madison Crutcher; Adam E Snook; Scott A Waldman
Journal:  Expert Rev Precis Med Drug Dev       Date:  2021-02-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.